Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone
With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform ANN ARBOR, MI / ACCESSWIRE / December 23, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform. Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum.
Dalrada Financial Corporation's Deposition Technology Makes Spectroptix(R) Available for Advance Ordering
Deptec's plasma spectrometer is primed to play an integral role in the booming semiconductor manufacturing and thin-film sectors. SAN DIEGO, CA / ACCESSWIRE / December 17, 2024 / Dalrada Financial Corporation (OTC PINK:DFCO), "Dalrada," "the Company"), announced today that Spectroptix®, a proprietary advanced plasma spectrometer developed by its subsidiary, Deposition Technology ("Deptec,"), is now available for advance ordering.
Neos S&P 500(R) High Income ETF Harnesses the Power of Options
Neos S&P 500(R) High Income ETF BATS: SPYI is an interesting play on the S&P 500 benchmarked to the CBOE's S&P 500 Buy-Write index. The Buy-Write index tracks potential returns from an S&P 500-oriented covered call strategy, which is the SPYI's primary focus.
Theralase(R) Launches Three New Clinical Study Sites in USA
Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®'s bladder cancer treatment TORONTO, ON / ACCESSWIRE / December 9, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched three new US-based Clinical Study Sites ("CSSs") for its bladder cancer registrational clinical study; specifically: Associated Medical Professionals of NY (Syracuse, New York), Urology of Indiana (Greenwood, Indiana) and Central Ohio Urology Group (Gahanna, Ohio). The Principal Investigators (" PIs ") for the Theralase® clinical study at the new CSSs are as follows: Associated Medical Professionals of NY - Ilija Aleksic, MD Dr. Aleksic graduated summa cum laude from the University at Buffalo and went on to complete medical school at SUNY Upstate Medical University.
Mace(R) Security International, Inc. Announces Completion of Going Private Merger with W Electric Intermediate Holdings, LLC
CLEVELAND, OH / ACCESSWIRE / December 6, 2024 / Mace Security International (OTCQB:MACE) (the "Company") announces the completion of the merger (the "Merger") contemplated by the Agreement and Plan of Merger (the "Merger Agreement") dated October 12, 2024 by and among W Electric Intermediate Holdings, LLC, a Delaware limited liability company ("Parent"), Mace Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), the Company and a representative of the Company's stockholders (the "Stockholders' Representative"). Charles A.
Mace(R) Security International, Inc. Announces Stockholder Approval of Merger with W Electric Intermediate Holdings, LLC
CLEVELAND, OH / ACCESSWIRE / December 5, 2024 / Mace Security International (OTCQB:MACE) (the "Company) announces the results of the Special Meeting of its stockholders held on December 3, 2024. At the Special Meeting, the Company's stockholders voted in favor of all proposals, including the proposal to adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement") by and among W Electric Intermediate Holdings, LLC, a Delaware limited liability company (the "Parent"), Mace Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (the "Merger Sub"), Mace and a representative of the Company's stockholders (the "Stockholders' Representative").
Theralase(R) Launches New Clinical Study Site in Canada
St. Joseph's Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®'s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / ACCESSWIRE / December 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched a new Clinical Study Site ("CSS") for its bladder cancer clinical study; specifically, St. Joseph's Healthcare Hamilton (Hamilton, Ontario, Canada). Theralase®'s lead drug, RuvidarTM (TLD-1433), activated by the TLC-3200 Medical Laser System ("TLC-3200") is currently under clinical investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin ("BCG")-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") with or without resected Ta / T1 papillary disease ("Study II").
Theralase(R) Release's 3Q2024 Financial Statements
TORONTO, ON / ACCESSWIRE / November 27, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's unaudited condensed consolidated interim financial statements for the nine-month period ended September 30, 2024. (" Financial Statements ").
Here's Why Investors Should Retain Ryder Stock Right Now
R's robust initiatives toward sustainability are praiseworthy. Shareholder-friendly approach too bodes well for R.
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% respectively, and in blood sugar, by 11.13% and 3.35% respectively. DehydraTECH-semaglutide compositions with and without SNAC technology outperformed Rybelsus® control in body weight Weight-control improvement demonstrated in ALL study groups during the final 4-weeks Outcomes are strongly supportive of pending Phase 1b Australian human study KELOWNA, BC / ACCESSWIRE / November 20, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received final 12-week body weight and blood sugar results from all 12 study groups of the recently completed diabetes animal study WEIGHT-A24-1 (the "Study").
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events Phase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025 BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented new TH104 clinical data at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024, underway in San Diego from November 15-19. The Phase 1 trial was a single-dose, single-center, open-label, randomized study of TH104 transmucosal buccal film conducted in two cohorts of patients with chronic liver disease (CLD), with the primary outcome of safety and tolerability.
Theralase(R) Closes Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / November 15, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On closing, the Corporation issued an aggregate of 2,221,334 Units at a price of $CAN 0.30 per Unit for aggregate gross proceeds of approximately $CAN 666,400.
